- Brain cancer
- Brain metastases
- Brain tumor
- Lymphoma
- Mycosis fungoides
- Primary brain tumor
- Spinal tumor
- Spine metastases
- Traumatic brain injury
- Edge radiosurgery
- Gamma knife
- Proton therapy
- Radiation therapy for CNS
- Stereotactic radiosurgery
Publications
Jonathan Baron, Gurbani Singh, Francesca Costabile, Carlos Chavez Perez, Miguel Perez-Guillermo Cuev, Emeline Chong, Colin Thomas, Jordan Carter, Sunita Nasta, Daniel Landsburg, Nektarios Kostopoulos, Stefan Barta, Jakub Svoboda, Stephen Schuster, Elise Chong, John Plastaras, Michael LaRiviere, Andrea Facciabene, Harper Hubbeling Low-Dose Hypofractionated Bridging Radiation (4Gy x 2 Fractions) Prior to CAR T-Cell Therapy for Relapsed/Refractory DLBCL , ASTRO 2026 annual meeting: 2026
Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma , Int J Part Ther: 2026
Baron J, Chelius M, Cohen L, Perez CC, Riina M, Ramesh S, Tierney A, Elghawy O, Hossain NM, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis , Pract Radiat Oncol: 2026
Linkowski L, Messing I, Berger M, Hollawell C, Friedes C, Alexander D, Wang X, Desai AS, Phillips RE, O'Rourke DM, Amankulor NM, Jackson C, Hubbeling H, Kurtz G, Bagley SJ, Bradley JD, Mohan S, Alonso-Basanta M, Lebow ES. Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series , J Radiat Oncol Biol Phys: 2026
Jonathan Baron, Monica Chelius, Gurbani Singh, Melanie Berger, Emeline Chong, Colin Thomas, Jordan Carter, Sunita Nasta, Daniel Landsburg, Stefan Barta, Jakub Svoboda, Stephen Schuster, Nikhil Yegya-Raman, Michael LaRiviere, John Plastaras, Elise Chong, Harper Hubbeling Safe Integration of Radiation Therapy with Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas , ASTRO 2026 Annual Meeting: 2026
Jonathan A Baron, Monica Chelius, MD; Gurbani Singh, MD; Michael D. Schad, MD; Melanie Berger, MD; Emeline R. Chong; Colin J. Thomas, MD; Jordan S. Carter, MD; Michael R. Cook, MD; Sunita D. Nasta, MD; Daniel J. Landsburg, MD; Stefan K. Barta, MD; Jakub Svoboda, MD; Stephen J. Schuster, MD; Nikhil Yegya-Raman, MD; Michael J. LaRiviere, MD; John P. Plastaras, MD, PhD; Elise A. Chong, MD; Harper Hubbeling, MD Safe Integration of Radiation Therapy with Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas , Clinical Lymphoma, Myeloma and Leukemia: 2026
Friedes C, Berger M, Linkowski L, Hollawell C, Hubbeling H, Alexander D, Kurtz G, Lustig RA, Dorsey JF, Desai AS, Phillips RE, Brem S, Davatzikos C, Nasrallah M, O'Rourke DM, Jackson C, Amankulor NM, Alonso-Basanta M, Mohan S, Bagley SJ, Lebow ES Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study , Neurooncol: 2026
Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma , Blood Adv: 2026
Baron JA, Cohen L, Chelius M, Messing I, Mallon J, Tierney A, Elghawy O, Hossain N, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma , Clin Lymphoma Myeloma Leuk: 2026
Thomas CJ, Myers CS, Chung J, Landsburg D, Nasta SD, Svoboda J, Chong EA, Schuster SJ, Carter J, Cook M, Tomasulo E, Elghawy O, LaRiviere M, Hubbeling H, Plastaras JP, Rook AH, Villasenor-Park J, Ruella M, Kim E, Barta SK Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden , Blood Neoplasia: 2026